Ligand Pharmaceuticals Reiterates FY25 Outlook - Update
I'm PortAI, I can summarize articles.
Ligand Pharmaceuticals, Inc. (LGND) has reiterated its adjusted earnings and revenue guidance for fiscal 2025 while reporting its first-quarter financial results. The company projects adjusted earnings between $6.00 and $6.25 per share, with revenues expected to range from $180 million to $200 million. Analysts anticipate earnings of $6.11 per share and revenues of $191.30 million for the year, excluding special items.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments